Oncomed Pharmaceuticals Inc., of Redwood City, Calif., presented final safety, efficacy and biomarker data from its phase Ib ALPINE trial testing tarextumab (anti-Notch2/3, OMP-59R5) in 40 patients with front-line metastatic pancreatic cancer, showing that the drug was generally well tolerated when administered with gemcitabine and Abraxane (nab-paclitaxel, Celgene Corp.), with manageable, on-target drug-related toxicities.